SCHEMBL24816239

SCHEMBL24816239

CCC1CCOC1(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28279048 0.78
SCHEMBL28103152 0.78
SCHEMBL3215267 0.78
SCHEMBL22520015 0.75 POLB (0.31)
SCHEMBL22519854 0.75 HTR2A (0.30)
SCHEMBL9129495 0.75 KDM4E (0.30)
SCHEMBL16642349 0.74
SCHEMBL30493775 0.73 KDM4E (0.32)
SCHEMBL27545251 0.72 NOS2 (0.30)
SCHEMBL27550673 0.72 NOS2 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691963-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2023-07-04 US disclosed
US-20220411403-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2022-12-29 US disclosed
CN-108137639-A Nicotinamide mononucleotide derivative and application thereof 麦德龙国际生物科技有限责任公司 2018-06-08 CN disclosed